Beckman Research Institute of City of Hope

Award Value
Research Training II: Michael Barish Research Training Program in Stem Cell Biology $2,500,143
Early Translational II: Yanhong Shi Developing a therapeutic candidate for Canavan disease using induced pluripotent stem cell $1,835,983
Disease Team Planning: Michael Barish Genetically-modified neural stem cells for treatment of high-grade glioma $55,000
Creativity Awards: Paul Salvaterra Creativity Award Program in Stem Cell Biology for California High School Students $207,251
Basic Biology IV: Yanhong Shi Modeling Alexander disease using patient-specific induced pluripotent stem cells $1,367,172
Early Translational III: Stephen Forman Targeting glioma cancer stem cells with receptor-engineered self-renewing memory T cells $5,217,004
Basic Biology III: Jiing-Kuan Yee Use of human iPS cells to study spinal muscular atrophy $1,268,868
New Faculty I: Tiziano Barberi Skeletal muscle development from hESC and its in vivo applications in animal models of muscular dystrophy $131,840
Tools and Technologies I: Larry Couture Development of Suspension Adaptation, Scale-up cGMP Banking and Cell Characterization Technologies for hESC Lines $882,929
SEED Grant: Timothy O'Connor Sources of Genetic Instability in Human Embryonic Stem Cells. $327,311
Disease Team Research I: John Zaia ZINC FINGER NUCLEASE-BASED STEM CELL THERAPY FOR AIDS $14,573,835
Disease Team Research I: Karen Aboody Stem Cell-mediated Therapy for High-grade Glioma: Toward Phase I-II Clinical Trials $18,015,429
Early Translational II: David DiGiusto Development of RNA-based approaches to stem cell gene therapy for HIV $3,124,130
Strategic Partnership III Track A: John Zaia A PHASE I, OPEN-LABEL STUDY TO ASSESS THE SAFETY, FEASIBILITY AND ENGRAFTMENT OF ZINC FINGER NUCLEASES (ZFN) CCR5 MODIFIED AUTOLOGOUS CD34+ HEMATOPOIETIC STEM/PROGENITOR CELLS (SB-728mR-HSPC) WITH ESCALATING DOSES OF BUSULFAN IN HIV-1 (R5) INFECTED SUBJEC $5,583,438
Total:
$55,090,333.00
Icon for xls export